Localised leishmaniasis of oral mucosa: report of an unusual clinicopathological entity.

Case Rep Dent

Department of Oral & Maxillofacial Surgery, Faculty of Dental Sciences, King George's Medical University, Lucknow, Uttar Pradesh 226003, India.

Published: October 2014

The term leishmaniasis comprises of a group of diseases caused by different species of a protozoan called Leishmania. There are three main clinical forms of leishmaniasis: visceral leishmaniasis, cutaneous leishmaniasis, and mucocutaneous leishmaniasis. Exclusive involvement of the mucosa is very rare. We present a case of mucosal leishmaniasis located in the oral cavity. The only manifestation of leishmaniasis disease in the described case was the appearance of an oral lesion. Treatment was provided in the form of antimoniates (oral miltefosine and systemic sodium stibogluconate). A review of literature is made on the subject.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197891PMC
http://dx.doi.org/10.1155/2014/753149DOI Listing

Publication Analysis

Top Keywords

leishmaniasis
7
localised leishmaniasis
4
oral
4
leishmaniasis oral
4
oral mucosa
4
mucosa report
4
report unusual
4
unusual clinicopathological
4
clinicopathological entity
4
entity term
4

Similar Publications

Introduction: Cutaneous Leishmaniasis (CL) is a zoonosis infection which is endemic in more than 100 countries in Asia, Africa, Europe and America. It was estimated that nearly 20 thousand of new cases are reported in Iran annually. This study aimed to investigate the impact of floods on the incidence of leishmaniasis in Golestan province (northeast of Iran) over nine years, from 2015 to 2023.

View Article and Find Full Text PDF

Bacterial infections commonly complicate cutaneous leishmaniasis (CL), worsening the disease and delaying healing. Despite this, there is a gap in research concerning the characteristics of pathogenic microorganisms associated in CL patients. This study aims to identify bacterial isolates and drug susceptibility patterns in CL patients.

View Article and Find Full Text PDF

Degradable Theranostic Polyurethane for Macrophage-Targeted Antileishmanial Drug Delivery.

Biomacromolecules

January 2025

Polymer Research Centre and Centre for Advanced Functional Materials, Department of Chemical Sciences, Indian Institute of Science Education and Research Kolkata, Nadia, Mohanpur 741246, West Bengal, India.

The present investigation aims to develop a reactive oxygen species (ROS) and esterase-responsive biodegradable mannosylated polyurethane to effectively deliver the encapsulated antileishmanial drug amphotericin B (AmB) selectively to infected macrophage cells. Owing to suitable amphiphilic balance, the as-synthesized glycosylated polyurethane () with aryl boronic ester-based diol () moiety as ROS-trigger, water-soluble mannose pendants, and fluorescent 4,4-difluoro-4-bora-3a,4a-diaza--indacene (BODIPY) chain ends for bioimaging formed nanoaggregates in an aqueous medium as confirmed by H NMR spectroscopy, dynamic light scattering (DLS), field emission scanning electron microscopy (FESEM), transmission electron microscopy (TEM), and critical aggregation concentration (CAC) measurements. Aided by two endogenous stimuli present in phagolysosome, ROS and esterase, AmB-encapsulated polymeric nanoaggregates as drug delivery vehicles achieved an efficient reduction of both and intracellular amastigote burden compared to the free AmB.

View Article and Find Full Text PDF

Progress in antileishmanial drugs: Mechanisms, challenges, and prospects.

PLoS Negl Trop Dis

January 2025

Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, China.

Leishmaniasis, a neglected tropical disease caused by Leishmania parasites, continues to pose global health challenges. Current treatments face issues like resistance, safety, efficacy, and cost. This review covers the discovery, mechanisms of action, clinical applications, and limitations of key antileishmanial agents: pentavalent antimonials, amphotericin B, miltefosine, paromomycin, and pentamidine.

View Article and Find Full Text PDF

Background: Leishmaniasis represents a significant parasitic disease with global health implications, and the development of an affordable and effective vaccine could provide a valuable solution. This study aimed to evaluate the immunogenicity of a DNA vaccine targeting Leishmania major specifically based on the Leishmania-activated C kinase (LACK) antigen, utilizing calcium phosphate nanoparticles (CaPNs) and chitosan nanoparticles (ChitNs) as adjuvants.

Methods: Seventy female BALB/c mice, aged 4-6 wk and weighing 20-22 g, were selected and divided into five groups, each consisting of 14 mice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!